Stay updated on BAT2206 vs Stelara in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the BAT2206 vs Stelara in Psoriasis Clinical Trial page.

Latest updates to the BAT2206 vs Stelara in Psoriasis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedLocations section updated to include Zhejiang as a study location, and Zhejiang Locations in the footer removed; the page revision updated to v3.3.3. The HHS Vulnerability Disclosure link was removed.SummaryDifference0.2%

- Check23 days agoNo Change Detected
- Check44 days agoChange DetectedThe page now shows a new revision label v3.3.2, replacing the previous v3.2.0. This update affects only versioning metadata and does not change the displayed study details.SummaryDifference0.1%

- Check52 days agoChange DetectedDeleted the notice about government funding and operating status from the page. The core study information, including eligibility criteria, endpoints, interventions, and results, remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check66 days agoChange DetectedThe updates appear to be cosmetic formatting or layout adjustments on the Study Details page and do not modify core trial information (design, eligibility criteria, interventions, outcomes, or enrollment). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check95 days agoChange Detected- Added a government-funding notice and current operating status guidance (including NIH Clinical Center details and links). - Updated version from v3.1.0 to v3.2.0.SummaryDifference4%

- Check102 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to BAT2206 vs Stelara in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BAT2206 vs Stelara in Psoriasis Clinical Trial page.